drugset / Trial / NCT04846478
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Phase 1
Active not recruiting
35 enrolled
Dana-Farber Cancer Institute
Epizyme, Inc. · collabNational Cancer Institute (NCI) · collabPfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: * Talazoparib * Tazemetostat
Timeline
- Start
- 2021-06-28
- Primary completion
- 2025-09-25
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | — | Oral |
| Subject | Tazemetostat | Small molecule | — | Oral |